Biochrom Ltd is a leading manufacturer of scientific instruments with over 40 years experience. The Biochrom Group consists of five well known instrument brands covering UV/Vis spectroscopy, microplate instrumentation and amino acid analysis. Our products are trusted by hospitals and laboratories worldwide and we are a valued OEM partner of many of the world’s finest scientific instrumentation companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

CELLARES AND POSEIDA THERAPEUTICS JOIN FORCES TO SPEED UP CELL THERAPY MANUFACTURING

Cellares Corporation | July 16, 2021

news image

Cellares Corporation, a life sciences technology company that has pioneered a revolutionary automated approach to cell therapy manufacturing announced today that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company that uses proprietary genetic engineering platform technologies to create cell and gene therapeutics with the potential to cure, has joined its Early Access Partnership Program (EAPP). Poseida joins PACT Pharma and academic partner Fred Hutchinson Cancer Research Cen...

Read More

Cell and Gene Therapy

BIOINVENT AND TRANSGENE RECEIVE CTA APPROVAL FOR PHASE L/LLA STUDY OF NOVEL ONCOLYTIC VACCINIA VIRUS BT-001

BioInvent | December 22, 2020

news image

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech organization focused in on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech organization that designs and develops infection based for the therapy of cancer, reported they have received administrative endorsement in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vacc...

Read More

TWINSTRAND BIOSCIENCES LAUNCHES DUPLEX SEQUENCING TECHNOLOGY

BioSpace | February 25, 2020

news image

TwinStrand Biosciences™, a next-generation DNA sequencing technology company, today announced the launch of TwinStrand Duplex Sequencing™ Technology kits at the annual Advances in Genome Biology and Technology (AGBT) General Meeting in Marco Island, Florida. At launch, the company will offer their platform technology for two research applications: detection of minimal residual disease in acute myeloid leukemia patients (AML MRD) and a multi-species genetic toxicology assay for rapid ...

Read More

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

news image

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More
news image

Cell and Gene Therapy

CELLARES AND POSEIDA THERAPEUTICS JOIN FORCES TO SPEED UP CELL THERAPY MANUFACTURING

Cellares Corporation | July 16, 2021

Cellares Corporation, a life sciences technology company that has pioneered a revolutionary automated approach to cell therapy manufacturing announced today that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company that uses proprietary genetic engineering platform technologies to create cell and gene therapeutics with the potential to cure, has joined its Early Access Partnership Program (EAPP). Poseida joins PACT Pharma and academic partner Fred Hutchinson Cancer Research Cen...

Read More
news image

Cell and Gene Therapy

BIOINVENT AND TRANSGENE RECEIVE CTA APPROVAL FOR PHASE L/LLA STUDY OF NOVEL ONCOLYTIC VACCINIA VIRUS BT-001

BioInvent | December 22, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech organization focused in on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech organization that designs and develops infection based for the therapy of cancer, reported they have received administrative endorsement in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vacc...

Read More
news image

TWINSTRAND BIOSCIENCES LAUNCHES DUPLEX SEQUENCING TECHNOLOGY

BioSpace | February 25, 2020

TwinStrand Biosciences™, a next-generation DNA sequencing technology company, today announced the launch of TwinStrand Duplex Sequencing™ Technology kits at the annual Advances in Genome Biology and Technology (AGBT) General Meeting in Marco Island, Florida. At launch, the company will offer their platform technology for two research applications: detection of minimal residual disease in acute myeloid leukemia patients (AML MRD) and a multi-species genetic toxicology assay for rapid ...

Read More
news image

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us